ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Development and validation of a personalized web-based calculator of aggressive recurrence after surgery for early-stage hepatocellular carcinoma by machine learning.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundAggressive recurrence (AR) is an important factor affecting prognosis after surgery for hepatocellular carcinoma (HCC). This study aimed to establish and evaluate a visual calculator to predict AR using by machine learning (ML) model.
methodsPatients diagnosed with HCC at an early stage were reviewed. The prediction ability of each model was evaluated using accuracy, sensitivity, specificity, precision, F1 score, and the area under the curve (AUC). Then, the model's prediction performance was evaluated by calibration curves, decision curve analysis (DCA), and precision-recall curves (PRC).
results483 patients were ultimately included in this study. The baseline characteristics indicate that patients in the AR group exhibit poorer liver function and more advanced tumor features. Then, nine risk features were identified and incorporated into the nine development models, respectively. Among the models, the XGBoost model showed the best prediction ability (AUC 0.986, 95% CI: 0.983-0.988). Calibration curves, DCA, and PRC further demonstrated the robust performance and clinical applicability. Then, A web-based calculator was built.
conclusionAn explainable XGBoost model to predict AR for patients with early-stage HCC after surgery was feasible and effective, suggesting its superior potential in tailoring surgical strategies and optimizing personalized postoperative treatment plans.
Indexed as
Identifiers
41276705What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.